Lifestance Health (LFST)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$12.73-0.78%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · LFST
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 6 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $13 LFST trades at 56× p/e — 2.4× the 23× p/e peer median. The market is re-rating it beyond its own range; our $11 fair value is low-confidence here. Analysts target $9.00–$19. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $13.00 | — | — | Analyst | high |
| Peer EV/EBITDA | 12M | $3.48 | 12.7 | 0.29 | TTM | high |
| Peer P/FCF | 12M | $8.79 | 21.3 | 0.41 | TTM | high |
| Peer P/E | 12M | $3.76 | 18.7 | 0.20 | ntm analyst | high |
| Peer P/S |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$9.00 – $19.00 (median $13.00) · 10 analysts · as of 2026-08-19
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $15.54 |
| 3.8 |
| 4.09 |
| TTM |
| high |
| triangulated | 12M | $5.60 | 22.9 | 0.24 | Triangulated | high |
| Peer P/E | 3Y | $4.35 | 18.7 | 0.23 | Analyst | medium |
| Peer P/S | 3Y | $21.78 | 3.8 | 5.73 | guidance | medium |
| Peer P/E | 5Y | $5.03 | 18.7 | 0.27 | Analyst | medium |
| Peer P/S | 5Y | $25.20 | 3.8 | 6.64 | guidance | medium |